RISDIPLAM (Evrysdi) a drug developed Genentech, a Roche subsidiary, was approved last August 7th, 2020 by the United States Food and Drug Administration. This is the third treatment currently on the market for Spinal Muscular Atrophy (SMA)
Risdiplam (Evrysdi) is a prescription medicine used to treat Spinal Muscular Atrophy (SMA) in adults and children 2 months of age and older.
Risdiplam (Evrysdi) (developed in collaboration with the SMA Foundation and PTC Therapeutics) is a small molecule used to increase the amount of SMN protein made by the SMN2 gene, commonly referred to as back up genes. Risdiplam is an orally given medication that prevents motor neuron degeneration and preserves muscle function. It is a liquid taken daily by mouth or feeding tube if required.
Click here for more information.